Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease market s | Novo Nordisk has reported the mixed midphase results behind its push to enter a heart disease ...
Four University of Rhode Island researchers have developed and tested a cost-effective, easy-to-use tabletop device that can ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback